Min-Chuan Huang

Min-Chuan Huang

Auto-generated profile, based on publicly available information

Min-Chuan Huang

Graduate Institute of Anatomy and Cell Biology, National Taiwan University College of Medicine, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2016 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
WHWan-Ling Ho
Wan-Ling Ho
WHWen-Ming Hsu
Wen-Ming Hsu
MHMin-Chuan Huang
Min-Chuan Huang
KKKenji Kadomatsu
Kenji Kadomatsu
ANAkira Nakagawara
Akira Nakagawara
Glycosylation is the most complex post-translational modification of proteins. Altered glycans on the tumor- and host-cell surface and in the tumor microenvironment have been identified to mediate critical events in cancer pathogenesis and progression. Tumor-associated glycan changes comprise increased branching of N-glycans, higher density of O-glycans, generation of truncated versions of normal counterparts, and generation of unusual forms of terminal structures arising from sialylation and fucosylation. The functional role of tumor-associated glycans (Tn, sTn, T, and sLea/x) is dependent on the interaction with lectins. Lectins are expressed on the surface of immune cells and endothelial cells or exist as extracellular matrix proteins and soluble adhesion molecules. Expression of tumor-associated glycans is involved in the dysregulation of glycogenes, which mainly comprise glycosyltransferases and glycosidases. Furthermore, genetic and epigenetic mechanisms on many glycogenes are associated with malignant transformation. With better understanding of all aspects of cancer-cell glycomics, many tumor-associated glycans have been utilized for diagnostic, prognostic, and therapeutic purposes. Glycan-based therapeutics has been applied to cancers from breast, lung, gastrointestinal system, melanomas, and lymphomas but rarely to neuroblastomas (NBs). The success of anti-disialoganglioside (GD2, a glycolipid antigen) antibodies sheds light on glycan-based therapies for NB and also suggests the possibility of protein glycosylation-based therapies for NB. This review summarizes our understanding of cancer glycobiology with a focus of how protein glycosylation and associated glycosyltransferases affect cellular behaviors and treatment outcome of various cancers, especially NB. Finally, we highlight potential applications of glycosylation in drug and cancer vaccine development for NB.

29 November 2011 in Cancer Research
Verified
Journal Article
Closed access
PDF file
YWYao-Ming Wu
Yao-Ming Wu
CLChiung-Hui Liu
Chiung-Hui Liu
RHRey-Heng Hu
Rey-Heng Hu
MHMiao-Juei Huang
Miao-Juei Huang
JLJian-Jr Lee
Jian-Jr Lee
MHMin-Chuan Huang
Min-Chuan Huang
Extracellular glycosylation is a critical determinant of malignant character. Here, we report that N-acetylgalactosaminyltransferase 2 (GALNT2), the enzyme that mediates the initial step of mucin type-O glycosylation, is a critical mediator of malignant character in hepatocellular carcinoma (HCC) that acts by modifying the activity of the epidermal growth factor receptor (EGFR). GALNT2 mRNA and protein were downregulated frequently in HCC tumors where these events were associated with vascular invasion and recurrence. Restoring GALNT2 expression in HCC cells suppressed EGF-induced cell growth, migration, and invasion in vitro and in vivo. Mechanistic investigations revealed that the status of the O-glycans attached to the EGFR was altered by GALNT2, changing EGFR responses after EGF binding. Inhibiting EGFR activity with erlotinib decreased the malignant characters caused by siRNA-mediated knockdown of GALNT2 in HCC cells, establishing the critical role of EGFR in mediating the effects of GALNT2 expression. Taken together, our results suggest that GALNT2 dysregulation contributes to the malignant behavior of HCC cells, and they provide novel insights into the significance of O-glycosylation in EGFR activity and HCC pathogenesis. Cancer Res; 71(23); 7270–9. ©2011 AACR.

1 May 2014 in Oral Oncology
Verified
Journal Article
Closed access
MLMei-Chun Lin
Mei-Chun Lin
MHMiao-Juei Huang
Miao-Juei Huang
CLChiung-Hui Liu
Chiung-Hui Liu
TYTsung-Lin Yang
Tsung-Lin Yang
MHMin-Chuan Huang
Min-Chuan Huang

1 December 1997 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
FLFang-Jen S. Lee
Fang-Jen S. Lee
CHChun-Fang Huang
Chun-Fang Huang
WYWei-Luen Yu
Wei-Luen Yu
LBLeh-Miauh Buu
Leh-Miauh Buu
CLChing-Yi Lin
Ching-Yi Lin
MVMartha Vaughan
Martha Vaughan
ADP-ribosylation factors (ARFs) are highly conserved ∼20-kDa guanine nucleotide-binding proteins that enhance the ADP-ribosyltransferase activity of cholera toxin and are believed to participate in vesicular transport in both exocytic and endocytic pathways. Several ARF-like proteins (ARLs) have been cloned fromDrosophila, rat, and human; however, the biological functions of ARLs are unknown. We have identified a yeast gene (ARL1) encoding a protein that is structurally related (>60% identical) to human, rat, and Drosophila ARL1. Biochemical analyses of purified recombinant yeast ARL1 (yARL1) protein revealed properties similar to those ARF and ARL1 proteins, including the ability to bind and hydrolyze GTP. Like other ARLs, recombinant yARL1 protein did not stimulate cholera toxin-catalyzed auto-ADP-ribosylation. yARL1 was not recognized by antibodies against mammalian ARLs or yeast ARFs. Anti-yARL1 antibodies did not cross-react with yeast ARFs, but did react with human ARLs. On subcellular fractionation, yARL1, similar to yARF1, was localized to the soluble fraction. The amino terminus of yARL1, like that of ARF, was myristoylated. Unlike Drosophila Arl1, yeastARL1 was not essential for cell viability. Like rat ARL1, yARL1 might be associated in part with the Golgi complex. However, yARL1 was not required for endoplasmic reticulum-to-Golgi protein transport, and it may offer an opportunity to define an ARL function in another kind of vesicular trafficking, such as the regulated secretory pathway.

30 September 2013 in Cancer Science
Verified
Journal Article
Open access
PDF file
WHWan‐Ling Ho
Wan‐Ling Ho
MCMei‐Ieng Che
Mei‐Ieng Che
CCChih‐Hsing Chou
Chih‐Hsing Chou
HCHsiu-Hao Chang
Hsiu-Hao Chang
YJYung-Ming Jeng
Yung-Ming Jeng
MHMin‐Chuan Huang
Min‐Chuan Huang
Aberrant expression of the simple mucin‐type carbohydrate antigens such as T, Tn, sialyl‐T and sialyl‐Tn is associated with poor prognosis in several cancers. β1,3‐N‐acetylglucosaminyltransferase‐3 (B3GNT3), a member of the β3GlcNAcT family, is responsible for forming extended core 1 (T antigen) oligosaccharides. The role of B3GNT3, which is expressed in various tissues including human fetal brain, in regulating neuroblastoma (NB) formation and cell behaviors remains unclear. Here, we showed that increased B3GNT3 expression evaluated using immunohistochemistry in NB tumor tissues correlated well with the histological grade of differentiation as well as a favorable Shimada's subset of pathology. Univariate and multivariate analyses revealed that positive B3GNT3 expression in tumor tissues predicted a favorable prognosis in NB patients independent of other prognostic markers. B3GNT3 overexpression suppresses T antigen formation and malignant phenotypes including migration and invasion of SK‐N‐SH cells, whereas B3GNT3 knockdown enhances these phenotypes of SK‐N‐SH cells. Moreover, B3GNT3 expression decreased phosphorylation of focal adhesion kinase (FAK), Src, paxillin, Akt and ERK1/2. We conclude that B3GNT3 predicts a favorable cancer behavior of NB and suppresses malignant phenotypes by modulating mucin‐type O‐glycosylation and signaling in NB cells.

1 August 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MWMartin K. Wild
Martin K. Wild
MHMin-Chuan Huang
Min-Chuan Huang
USUrsula Schulze-Horsel
Ursula Schulze-Horsel
PMP. Anton van der Merwe
P. Anton van der Merwe
DVDietmar Vestweber
Dietmar Vestweber
E-selectin is an endothelial adhesion molecule, which mediates the tethering and rolling of leukocytes on vascular endothelium. It recognizes the glycoprotein E-selectin ligand-1 (ESL-1) as a major binding partner on mouse myeloid cells. Using surface plasmon resonance, we measured the kinetics and affinity of binding of monomeric E-selectin to ESL-1 isolated from mouse bone marrow cells. E-selectin bound to ESL-1 with a fast dissociation rate constant of 4.6 s−1 and a calculated association rate constant of 7.4 × 104 m −1s−1. We determined a dissociation constant (K d) of 62 μm, which resembles the affinity of L-selectin binding to glycosylation-dependent cell adhesion molecule-1. The affinity of the E-selectin-ESL-1 interaction did not change significantly when the temperature was varied from 5 °C to 37 °C, indicating that the enthalpic contribution to the binding is small at physiological temperatures, and that, in contrast to typical protein-carbohydrate interactions, binding is driven primarily by favorable entropic changes. Interestingly, surface plasmon resonance experiments with recombinant ESL-1 from α1,3-fucosyltransferase IV-expressing Chinese hamster ovary cells showed a very similar K d of 66 μm, suggesting that this fucosyltransferase is sufficient to produce fully functional recombinant ESL-1. Following the recent description of the affinity and kinetics of the selectin-ligand pairs L-selectin-glycosylation-dependent cell adhesion molecule-1 and P-selectin-P-selectin glycoprotein ligand-1, this is the first determination of the parameters of E-selectin binding to one of its naturally occurring ligands.